FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386986427> ?p ?o ?g. }

• W4386986427 endingPage "S90" @default.
• W4386986427 startingPage "S89" @default.
• W4386986427 abstract "Purpose High-dose-rate (HDR) brachytherapy is a vital part of treatment in patients with locally advanced cervical cancer. Current guidelines recommend the use of image-guided adaptive brachytherapy (IGABT). Several fractionation schedules are used in external beam radiotherapy (EBRT) and brachytherapy (BT). A retrospective analysis of patients treated with radio(chemo)therapy and HDR brachytherapy due to cervical cancer was conducted. We compared the efficacy of two fractionation schedules implemented in our department. Materials and Methods Schedule one (5x6 Gy) consisted of five fractions of 6 Gy delivered within 2.5 weeks. In the majority of patients, the dose was prescribed to point A. Schedule two (4x7 Gy) consisted of four fractions of 7 Gy delivered within two weeks. In all patients, the dose was prescribed to CTV. Local control (LC) and distant metastasis-free survival (DMFS) were calculated. The Kaplan-Meier estimator, log-rank and Mann-Whitney U test were used in statistical analysis. One hundred seventeen patients were included in this analysis. Median age was 57 years (range: 29 - 79). The disease stage was re-assessed according to FIGO 2018 classification. Forty-five percent of patients had FIGO IIIC1 disease, 29% - FIGO IIIB, 15% - FIGO IIB and 6% - FIGO IIIC2. The vast majority of patients (96%) had were diagnosed with planoepithelial carcinoma, 2,5% with cervical adenocarcinoma, one patient with clear cell carcinoma and one with serous carcinoma. The 5x6 Gy fractionation was administered in 79% of patients. The median overall treatment time (OTT) was 58 days (range: 45 - 139 days). The median CTV D90 EQD2 sum of EBRT and BT was 89 Gy (range: 65 - 114 Gy). Results In the 5x6 Gy subgroup, the follow-up was significantly longer (p=0.00006), CTV D90 EQD2 was significantly higher (p=0.0001), and OTT was significantly longer (p=0.02). No other significant differences were observed between the subgroups. They were well balanced in terms of patients' age (p=0.6), histopathological grade of the tumour (p=0.2) and FIGO stage (p=0.07). In the whole group, 5-year LC was 91%, 5-year regional nodal control was 86%, and 5-year DMFS was 80%. The comparison of the two fractionation schedules (5x6 Gy vs 4x7 Gy) revealed that higher CTV D90 EQD2 was not associated with better local or distant control. There were no differences in LC (p=0.79), regional nodal control (p=0.7) or DMFS (p=0.83) between the subgroups. However, better regional nodal control and longer DMFS were observed in patients with OTT≤60 days (p=0.035 and p=0.017, respectively). Conclusions Both fractionation schedules have similar efficacy. A shorter overall treatment time is associated with better regional nodal control and DMFS. However, a longer follow-up is needed to confirm these findings. High-dose-rate (HDR) brachytherapy is a vital part of treatment in patients with locally advanced cervical cancer. Current guidelines recommend the use of image-guided adaptive brachytherapy (IGABT). Several fractionation schedules are used in external beam radiotherapy (EBRT) and brachytherapy (BT). A retrospective analysis of patients treated with radio(chemo)therapy and HDR brachytherapy due to cervical cancer was conducted. We compared the efficacy of two fractionation schedules implemented in our department. Schedule one (5x6 Gy) consisted of five fractions of 6 Gy delivered within 2.5 weeks. In the majority of patients, the dose was prescribed to point A. Schedule two (4x7 Gy) consisted of four fractions of 7 Gy delivered within two weeks. In all patients, the dose was prescribed to CTV. Local control (LC) and distant metastasis-free survival (DMFS) were calculated. The Kaplan-Meier estimator, log-rank and Mann-Whitney U test were used in statistical analysis. One hundred seventeen patients were included in this analysis. Median age was 57 years (range: 29 - 79). The disease stage was re-assessed according to FIGO 2018 classification. Forty-five percent of patients had FIGO IIIC1 disease, 29% - FIGO IIIB, 15% - FIGO IIB and 6% - FIGO IIIC2. The vast majority of patients (96%) had were diagnosed with planoepithelial carcinoma, 2,5% with cervical adenocarcinoma, one patient with clear cell carcinoma and one with serous carcinoma. The 5x6 Gy fractionation was administered in 79% of patients. The median overall treatment time (OTT) was 58 days (range: 45 - 139 days). The median CTV D90 EQD2 sum of EBRT and BT was 89 Gy (range: 65 - 114 Gy). In the 5x6 Gy subgroup, the follow-up was significantly longer (p=0.00006), CTV D90 EQD2 was significantly higher (p=0.0001), and OTT was significantly longer (p=0.02). No other significant differences were observed between the subgroups. They were well balanced in terms of patients' age (p=0.6), histopathological grade of the tumour (p=0.2) and FIGO stage (p=0.07). In the whole group, 5-year LC was 91%, 5-year regional nodal control was 86%, and 5-year DMFS was 80%. The comparison of the two fractionation schedules (5x6 Gy vs 4x7 Gy) revealed that higher CTV D90 EQD2 was not associated with better local or distant control. There were no differences in LC (p=0.79), regional nodal control (p=0.7) or DMFS (p=0.83) between the subgroups. However, better regional nodal control and longer DMFS were observed in patients with OTT≤60 days (p=0.035 and p=0.017, respectively). Both fractionation schedules have similar efficacy. A shorter overall treatment time is associated with better regional nodal control and DMFS. However, a longer follow-up is needed to confirm these findings." @default.
• W4386986427 created "2023-09-24" @default.
• W4386986427 creator A5073514539 @default.
• W4386986427 date "2023-09-01" @default.
• W4386986427 modified "2023-10-03" @default.
• W4386986427 title "PO47" @default.
• W4386986427 doi "https://doi.org/10.1016/j.brachy.2023.06.148" @default.
• W4386986427 hasPublicationYear "2023" @default.
• W4386986427 type Work @default.
• W4386986427 citedByCount "0" @default.
• W4386986427 crossrefType "journal-article" @default.
• W4386986427 hasAuthorship W4386986427A5073514539 @default.
• W4386986427 hasConcept C121608353 @default.
• W4386986427 hasConcept C126322002 @default.
• W4386986427 hasConcept C126838900 @default.
• W4386986427 hasConcept C126894567 @default.
• W4386986427 hasConcept C141071460 @default.
• W4386986427 hasConcept C146357865 @default.
• W4386986427 hasConcept C151730666 @default.
• W4386986427 hasConcept C167135981 @default.
• W4386986427 hasConcept C2775908122 @default.
• W4386986427 hasConcept C2777416452 @default.
• W4386986427 hasConcept C2777546739 @default.
• W4386986427 hasConcept C2778220009 @default.
• W4386986427 hasConcept C2989005 @default.
• W4386986427 hasConcept C2993195994 @default.
• W4386986427 hasConcept C509974204 @default.
• W4386986427 hasConcept C71924100 @default.
• W4386986427 hasConcept C86803240 @default.
• W4386986427 hasConceptScore W4386986427C121608353 @default.
• W4386986427 hasConceptScore W4386986427C126322002 @default.
• W4386986427 hasConceptScore W4386986427C126838900 @default.
• W4386986427 hasConceptScore W4386986427C126894567 @default.
• W4386986427 hasConceptScore W4386986427C141071460 @default.
• W4386986427 hasConceptScore W4386986427C146357865 @default.
• W4386986427 hasConceptScore W4386986427C151730666 @default.
• W4386986427 hasConceptScore W4386986427C167135981 @default.
• W4386986427 hasConceptScore W4386986427C2775908122 @default.
• W4386986427 hasConceptScore W4386986427C2777416452 @default.
• W4386986427 hasConceptScore W4386986427C2777546739 @default.
• W4386986427 hasConceptScore W4386986427C2778220009 @default.
• W4386986427 hasConceptScore W4386986427C2989005 @default.
• W4386986427 hasConceptScore W4386986427C2993195994 @default.
• W4386986427 hasConceptScore W4386986427C509974204 @default.
• W4386986427 hasConceptScore W4386986427C71924100 @default.
• W4386986427 hasConceptScore W4386986427C86803240 @default.
• W4386986427 hasIssue "5" @default.
• W4386986427 hasLocation W43869864271 @default.
• W4386986427 hasOpenAccess W4386986427 @default.
• W4386986427 hasPrimaryLocation W43869864271 @default.
• W4386986427 hasRelatedWork W1966946680 @default.
• W4386986427 hasRelatedWork W2087456254 @default.
• W4386986427 hasRelatedWork W2404243584 @default.
• W4386986427 hasRelatedWork W2916147875 @default.
• W4386986427 hasRelatedWork W2966036943 @default.
• W4386986427 hasRelatedWork W3029213237 @default.
• W4386986427 hasRelatedWork W3029595631 @default.
• W4386986427 hasRelatedWork W3104537559 @default.
• W4386986427 hasRelatedWork W3110899715 @default.
• W4386986427 hasRelatedWork W4206581437 @default.
• W4386986427 hasVolume "22" @default.
• W4386986427 isParatext "false" @default.
• W4386986427 isRetracted "false" @default.
• W4386986427 workType "article" @default.